alphavestcapital.com

$nwbo @alphavestcap x.com/alphavestcap/s… cambridgenetwork.co.uk/news/mayor-bac… Mayor backs budding Cambridge x Manchester partnership to drive local and national growth 📷Mayor of Cambridgeshire and Peterborough, Paul Bristow, joined partners in Manchester last week as part of the next phase of the Cambridge x Manchester Innovation Partnership, a city-to-city collaboration fostering innovation and growth.Established last year between the Universities of Cambridge and Manchester, the two-day programme and first formal board meeting included Mayor of Greater Manchester Andy Burnham and leaders from businesses including Shaun Grady, UK Chair of AstraZeneca, local authorities and innovation organisations across the two cities.Further momentum is gathering behind the partnership’s shared ambition to turn world-leading research and innovation into jobs, new investment and economic growth which delivers real benefits for local people.Both cities’ economies bring complementary strengths. Cambridge is a global centre for leading research and discovery, with global investment pull, and Manchester offers scale, space, talent and a strong track record innovation into commercial success.By working together, both regions aim to be greater than the sum of their parts and deliver benefits well beyond their own boundaries, including supporting the Government’s mission to grow the national economy.For Cambridgeshire and Peterborough, the partnership directly supports the ambitions set out in the Local Growth Plan, which focuses on growing the economy, upgrading transport and other key infrastructure and ensuring that growth benefits local people and communities. The plan sets out a mayoral ambition to triple the size of the local economy by 2050.Building strong cross-regional partnerships is part of that ambition, helping to attract investment, strengthen innovation ecosystems and make the case for infrastructure and skills investment.The Mayor took part in the first formal meeting of the partnership, alongside Mayor Burnham, university leaders from Cambridge and Manchester, and senior figures from business and innovation. Discussions focused on shared priorities including life sciences, advanced materials, creative industries and digital innovation, as well as the importance of growth which makes a difference to people’s lives.The two-day programme also showcased how collaboration can work in practice, including knowledge-sharing on transport, with Manchester’s experience of the Metrolink system and Cambridge’s ongoing work to explore mass transit options to support future growth. Light rail for Cambridge is one of Paul Bristow’s manifesto pledges.Other sessions including the creative and cultural innovation economy and how they can be better embedded in the science and tech sectors. Paul Bristow said: “The partnership is hugely ambitious for our respective regions and has everything to gain from working together in this way.“Building partnerships like this which seek to drive up innovation and investment will be crucial in unlocking the potential of our economy set out in the Local Growth Plan.“This is about regions backing each other, sharing what works and ensuring growth brings benefits to all our communities.” Professor Deborah Prentice, Vice-Chancellor of the University of Cambridge, said last week: “The Cambridge x Manchester partnership brings together two great universities and cities with complementary strengths and the will to work together. We are already showing how connected ecosystems can drive innovation, investment and inclusive growth. This week’s meetings underline the momentum behind our shared ambition and the firm foundations being laid for the next phase of work.” Kathryn Chapman, Executive Director, Innovate Cambridge, said: "Cambridge and Manchester have deep histories of innovation, with complementary strengths that span the full journey from discovery to scale. By combining Cambridge’s track record in transformational early-stage companies and attraction of capital with Manchester’s strength in development, application and deployment across markets, this partnership will help shape the UK’s future economic growth"The Cambridge x Manchester Partnership will continue to develop through further joint activity, helping position both regions at the heart of the UK’s future economic growth

x.com/peter_brit/sta… $nwbo @alphavestcap

@alphavestcap $nwbo Advent Bioservices Quality Manager, Apheresis Clinic London Area, United Kingdom · 1 month ago · 24 people clicked apply Full-time No longer accepting applications We are seeking a Quality Manager who will be responsible for providing leadership and subject matter expertise to the Apheresis Clinic, to ensure that the facility operates to the highest standards of quality governance, regulatory compliance, and patient safety. The role leads the Quality Management System (QMS) for apheresis, drives continuous improvement, and ensures alignment with HTA licensing requirements, CQC accreditation standards, local policies, and applicable GxP/GMP expectations across the end-to-end cellular therapy pathway. This is a fantastic opportunity for an enthusiastic, driven and experienced Quality Manager wanting to join an established organisation. Company Information Advent Bioservices is an HTA licenced Contract Development and Manufacturing Organisation (CDMO) providing GMP manufacturing of ATMPs and related products, process development and ancillary services, currently establishing a satellite apheresis clinic in London. We support the development of complex, breakthrough therapies for a globally diverse market. We are at the forefront of revolutionary medicine in which life-threatening diseases are treated using highly personalised therapies. Job Summary Based in London, the purpose of this role is to lead the quality management system and governance of an apheresis clinic in London. The successful candidate will work within a fast-paced multidisciplinary HTA/ GxP / GMP environment ensuring all documentation and information is processed in line with these requirements. You will have the following experience/qualifications Must have knowledge of clinical aspects of cell therapies and apheresis operations Must have experience of incident investigation, root cause analysis and CAPA management​ Must have direct experience in cellular therapy/apheresis collection facilities and/or working within an HTA licensed establishment. Must have strong organisational skills and ability to prioritise, work under pressure Must have excellent attention to detail Line management experience would be advantageous Travel between Advent’s London and Sawston sites may be required. ​ We are not accepting agency applications for this role … more Set alert for similar jobs Quality Assurance Manager, London Area, United Kingdom

$nwbo @alphavestcap @alphavestcap x.com/paulbristow79/… 16h ADVENT BIOSERVICES - SAWSTONGreat visit(@paulbristow79) in #Sawston to Advent Bioservices & Northwest Biotherapeutics who are working on cancer immunotherapies for brain tumors. This is personal. My dad died of a brain tumour & I shall do whatever I can to help them scale up & grow. 💙 investorshub.advfn.com/boards/read_ms… x.com/alphavestcap/s… ATLnsider Re: Lolo_Ferrari post# 821330 Tuesday, April 14, 2026 8:41:06 PM I believe that the Mayor of Peterborough and Cambridgeshire (like most NWBO Longs) believes that DCVax-L will be approved by the MHRA. Then, NWBio, Advent Bioservices, and the Sawston Facility will provide hundreds if not thousands of jobs to his local constituents in the greater Cambridge area, and this will be a boon to the local economy. 📷

$nwbo @alphavestcap pgsd Høeg touts FDA efforts to speed rare disease drugs to market: April 14, 2026 ARLINGTON, VA – The top drug regulator at the US Food and Drug Administration (FDA) said the agency is working to develop new pathways for rare diseases to reduce regulatory barriers for medical products and emphasized the need to challenge medical dogma. Tracy Beth Høeg, the acting director for the Center for Drug Evaluation and Research (CDER), was the keynote speaker at the 2026 National Organization for Rare Diseases (NORD) Rare Disease Scientific Symposium, where she said the Trump administration is working to speed new products to market. Høeg, a dual citizen of the US and Denmark, noted that when she moved back to the US during the COVID-19 pandemic, she questioned the US' response to the pandemic based on her experience in Denmark. In particular, she questioned the need for school closures and mask mandates, which led her to publish several studies in collaboration with other researchers and brought her into contact with current FDA Commissioner Marty Makary and Vinay Prasad, the outgoing director of the Center for Biologics Evaluation and Research, both of whom have voiced similar skepticism about COVID-19 public health mandates. "I believe very strongly in retaining the integrity of the scientific process and keeping it apoliticized," said Høeg. "Whether a drug is effective or ineffective, we must communicate those results and be transparent and honest. "One of our biggest roles and challenges of the FDA is effective communication about how we are evaluating the data," she added. Høeg listed several initiatives FDA is undertaking, including efforts to reduce animal testing. The agency recently announced draft guidance to assist pharmaceutical manufacturers in transitioning from animal studies to non-animal alternatives for drug development. It is urging companies to adopt new approach methodologies (NAMs), incorporating in vitro human-based systems, such as organs-on-chips and in silico modeling, to assess drug safety. (RELATED: FDA drafts guidance on animal testing alternatives, Regulatory Focus 18 March 2026) "I think that this is also very important in drug development in the rare disease space to save time, money, and also to use and develop more predictive methodologies of toxicology and safety in humans, and that we can move towards novel methodologies to better predict what we're going to see," said Høeg. "This is going to allow drugs to come to the market much faster." Høeg also highlighted FDA's recent announcement in the New England Journal of Medicine (NEJM) to require only one clinical trial to demonstrate that a product meets its regulatory requirements for safety and efficacy in most cases by default. She noted that this was already the case for rare disease drug development, but now the agency will accept data from single clinical trials for any product if the researchers demonstrate that their trials are well-designed and can provide sufficient evidence. (RELATED: Experts react to FDA’s shift to single pivotal trials for most drugs, Regulatory Focus 18 February 2026) Additionally, Høeg mentioned FDA is working to finalize guidance on external controls and is seeking feedback on a proposed guidance on a plausible mechanism of action pathway for ultra-rare diseases by 27 April. She also said that CDER and CBER plan to host a workshop on the proposed pathway soon. According to the latest FDA data, Høeg said approval times from the time an application is first filed have dropped below 400 days, despite the mass firings at the agency over the past year. She noted that during COVID-19, the agency's approval times were even shorter and emphasized that Makary wants to treat serious diseases and rare diseases as urgent public health matters to speed products to market. Høeg admitted that before coming to the FDA, she had an outsider's perspective of the agency and didn't fully appreciate the work the agency does or its staff. "That has been my biggest surprise, it's the quality of the scientists and the work that is being done there and the care that goes into these approvals," she said. "I feel one of my jobs is to communicate that with the public, that there are extremely caring and competent, highly intelligent, experienced people working at the FDA, and I'm proud to work with them." Adaptive trials and external controls On the topic of developing products for ultra-rare diseases, Olivia Morgan, an FDA statistician, provided an overview of the agency’s approach to adaptive clinical trial designs for such products and offered tips on how to address the issue. She noted that it is difficult to propose a fixed maximum sample size for such trials and said sponsors may need to plan for interim trial adaptations, including sample size re-estimation and subpopulation selection. She also highlighted some analysis considerations specific to adaptive trials, including controlling for Type I error rates, considerations about asymptotic assumptions for small sample sizes, conducting a simulation study, and more. More broadly, Morgan said sponsors of ultra-rare disease trials must consider the impact of the small patient population, adapt to efficiently enroll potential trial subjects, control Type I error, prespecify the analysis plan, and evaluate whether asymptomatic normality is a reasonable assumption. If not, they should use analysis methods that don't rely on the assumption. Wonyul Lee, a senior statistical reviewer at CDER, spoke at a later session about FDA's perspective on externally controlled trials where outcomes in patients receiving the test treatment are compared to outcomes in people outside the trial who have not received the same treatment. He noted that the agency published a draft guidance in December 2019 on demonstrating substantial evidence of effectiveness that sponsors should reference when considering conducting externally controlled trials. Lee outlined design considerations for externally controlled trials as well as data considerations. He emphasized that the design stage is critical to successful externally controlled trials and said sponsors should carefully assess whether such trials are truly suitable to their needs, address potential sources of bias when designing them, and finalize their protocol and analysis plan before initiating the trials. Lee also noted that external control data should include sufficient information to support comprehensive comparability assessments, and that sponsors should engage with the relevant FDA review division early in the drug development program, before initiating trials raps.org/resource/h-eg-…

📷 $NWBO @alphavestcap Every day, Oliver Dorigo, MD, PhD, has to confront the challenge of treating ovarian cancer, which is a frustratingly stubborn disease to manage. It’s hard to detect, at times resistant to drug treatment and, all too often, fatal. “I don’t accept the fact that at least 60% of patients with ovarian cancer die from the disease. We need to change that. That has been my mission for decades,” said Dorigo, the Mary Lake Polan Professor at Stanford Medicine. “I’m very optimistic that there will be a time when we will be able to offer patients more effective therapies.” That optimism springs from Dorigo’s recent work with two innovative therapies now in clinical trials that he hopes will improve the outlook for patients with the disease, one of the deadliest cancers among women. Some 21,000 women are diagnosed with ovarian cancer every year in the United States and, in 2026 alone, some 12,450 are expected to die from it, according to the American Cancer Society. Because no definitive screening tools exist, patients are often diagnosed when the cancer is advanced, making it particularly difficult to treat, said Dorigo, director of the gynecologic oncology division. Patients might initially respond to treatment, which typically includes surgery and multiple rounds of chemotherapy. But the cancer frequently returns and can cause patients to become resistant to drug treatment, leaving them with few therapeutic options, he said. Among patients with advanced disease, only about one-third live at least five years. To change that, Dorigo and his colleagues have turned to CAR-T (chimeric antigen receptor) cell therapy, which is transforming cancer treatment. The therapy empowers a patient’s own immune system to attack cancer cells. It has been used with tremendous success in blood cancers, with clinicians just starting to test it in solid tumors. “I don’t accept the fact that at least 60% of patients with ovarian cancer die from the disease. We need to change that. That has been my mission for decades.”Oliver Dorigo, MD, PhD, the Mary Lake Polan Professor at Stanford Medicine “Ovarian cancer is one of these cancers that has been left behind in the immunotherapy revolution. It’s unfortunate because we need a breakthrough,” said Crystal Mackall, MD, founding director of the Stanford Center for Cancer Cell Therapy and a national leader in the field. “There’s no reason we shouldn’t be able to apply this in ovarian cancer.” The therapy, which they are testing in a clinical trial, targets a protein called B7-H3, which is expressed in 90% of ovarian cancers, Mackall said. During treatment, clinicians extract a patient’s white blood cells — the disease fighters of the immune system — and genetically modify them in the lab to recognize the B7-H3 protein. The new, highly active cells are then infused into the patient so they can zero in on and destroy cancerous cells. Ovarian cancer is often confined to the abdomen, so clinicians can infuse the cells directly into that area using a soft tube, thus sparing other tissues. “This might have an advantage,” said Mackall, the Ernest and Amelia Gallo Family Professor and a professor of pediatrics and of medicine, who is collaborating in the trial. “We have seen this in brain tumors. Giving the CAR-T cells directly into the brain is shown to have benefit.” The researchers began the trial in late 2024 and have tested the treatment in seven patients, all with advanced, recurring disease that has resisted all other therapies. In all patients, the tumors stopped growing for some time, and in some, tumors decreased after two months, Dorigo said. “We have definitely seen initial benefits to patients — some positive signals,” he said. Dorigo noted that some patients in the trial experienced side effects related to the hyperactivity of the T cells, which can cause fever, low blood cell counts and leg swelling. To reduce these side effects, the research team has lowered the dose of the CAR-T cells. That made the treatment more tolerable while still controlling tumor growth, Dorigo said. Patients receive as many as three infusions to maximize the impact of the CAR-T cells, he said. The researchers now plan to treat up to 10 additional patients in the trial at the lower dose. “Ovarian cancer is one of these cancers that has been left behind in the immunotherapy revolution. It’s unfortunate because we need a breakthrough. There’s no reason we shouldn’t be able to apply this in ovarian cancer.”Crystal Mackall, MD, founding director of the Stanford Center for Cancer Cell Therapy By summer 2026, the researchers may also begin using a next-generation CAR-T cell whose activity can be regulated through a daily pill that turns the T cells on and off, Mackall said. This approach, developed in her laboratory, enables patients to use the pill to tune the potency of the T cells. For instance, a patient who begins to experience toxic side effects can stop taking the pill for a few days to modulate the dose and eliminate the toxicity, Mackall said. She believes the trial is a good starting point for treating a disease with an urgent need for new approaches. “I think it’s an exciting target in a disease that doesn’t have a lot of options,” she said. “This is something we can offer to the field that has yet to be available. One of the advantages is that we have a great team focused on women’s cancers. I can’t emphasize that enough. It allows us to learn a lot from our patients. I think this is step one. We are in it for the long haul.” Because this trial was initiated by Stanford Medicine, using a $5 million gift from a donor, the researchers have full control over how it’s conducted. “We are the ones who can modify the treatment on our study protocol,” Dorigo said. “We can therefore be very flexible and react to clinical observations quickly. It’s very different when a company sponsors a trial, where we are subject to their strategies and thinking.” In a separate effort, Dorigo is testing an antibody discovered in the laboratory  of Irving Weissman, MD, the Virginia & D.K. Ludwig Professor in Clinical Investigation in Cancer Research at Stanford Medicine, and his colleagues. He’s participating in a multi-center trial sponsored by Pheast Therapeutics Inc., which was co-founded by scientists who trained in Weissman’s lab. Weissman’s team identified a protein on the surface of cancer cells, called CD24, that allows them to escape destruction by immune cells called macrophages. The researchers devised an anti-CD24 antibody that removes this obstacle, allowing the macrophages to gobble up and destroy the cells. Ovarian cancer is a good target for this therapy, Dorigo said, as these tumors express high levels of CD24 and contain a lot of macrophages. So far, five patients have been treated with the anti-CD24 antibody at the Stanford Women’s Cancer Center. The goal is to determine if the drug is safe and shows any anti-tumor activity. The trial began in July 2025 so it’s too early to draw conclusions. Patients treated at Stanford and other institutions have tolerated the treatment well so far, Dorigo said. These two Stanford Medicine trials are encouraging, as they represent a whole new direction for immune-based therapies, said Anne Mette Buhl, PhD, senior director for treatment access and scientific education with Ovarian Cancer Research Alliance. “This is a particularly hopeful time for the ovarian cancer community, as substantial efforts are underway to develop more effective and precise treatment options,” she said. Spotlight on Crystal Mackall Professor of pediatrics and of medicine A pioneer in cancer immunotherapy, Crystal Mackall was among the first to show the value of CAR-T cells in pediatric leukemia, while working at the National Institutes of Health. More recently, she and Stanford Medicine colleagues showed these cells could be used to treat certain brain tumors. She has published multiple landmark papers in the field. Came to Stanford Medicine in 2016 from the NIH and founded the Center for Cancer Cell Therapy in 2017. Grew up in northeastern Ohio, in a working-class family. Received her MD degree from Northeast Ohio Medical University. Recharges by spending time with family, hiking, doing other outdoor activities, reading and enjoying a good meal. In her words: “This work matters to me because I believe that cell therapies can have activity on more common solid cancers where we have major unmet needs. I think ovarian cancer is a good setting to test that.” Spotlight on Oliver Dorigo Director of the gynecologic oncology division Oliver Dorigo treats patients with gynecologic cancers, including ovarian, cervical, endometrial, vaginal and vulva cancer. His research and the clinical trials he leads  are designed to develop and study new immunotherapies for patients with ovarian cancer. Received his MD degree from the University of Heidelberg in Germany and a PhD in molecular biology from the University of California, Los Angeles. Was born and raised in Germany by a German mother and an Italian father, and still visits family in Italy and Germany. Has completed 21 full Ironman triathlons (2.4 miles swimming, 112 miles cycling, 26.2 miles running). To relax, he bikes, runs, swims, skis, surfs and spends time with family, including his three teenagers. “Everybody needs something to get their minds off the very challenging situations we encounter in patient care. Sports and family keep me active and give me something to look forward to.” In his words: “I’ve treated ovarian cancer for decades. I see every day how challenging this treatment is for the patients and their families. We still lose way too many patients to this disease. For the patients and even for myself, it’s extremely frustrating to come to the end with no more options. We need more cures. With time, I am confident that we will get there.”

$nwbo @alphavestcap Ship ‘Spoofing’ in Strait of Hormuz May Compound Confusion A new pattern of deceptive activity by some vessels around the critical waterway suggests the new American blockade is changing how some ships linked to Iran are behaving. A cargo ship off the coast of Ras al-Khaimah, United Arab Emirates, on Monday.Credit...Agence France-Presse — Getty Images📷 📷 By Ephrat Livni April 14, 2026 See more of our coverage in your search results.Add The New York Times on Google Maritime intelligence experts are starting to see a new pattern of “shadow” activity in waters in and around the Strait of Hormuz since the United States naval blockade on vessels coming in and out of Iranian ports went into effect on Monday, suggesting that more ships seem to be adopting tactics to avoid detection than during the previous weeks of war.“Now, we are starting to see vessels going dark or using ‘zombie’ or random identification,” said Ami Daniel, the chief executive of Windward, a maritime intelligence data provider, in an interview on Tuesday.In the weeks after the American-Israeli attack on Iran in late February, Iranian exports went “uninterrupted” and had “almost no need to go off radar,” Mr. Daniel said. But in the past 24 hours, more ships appear to be manipulating the global system intended to keep tabs on vessel activity and traffic, suggesting that some vessels linked to Iran are being “a bit more cautious,” he said.Under international maritime law, most large commercial vessels must travel with a transponder that automatically transmits the ship’s name, location, route and other identifying information. That includes a 9-digit number with a country code, which serves as a digital fingerprint for a ship.AdvertisementSKIP ADVERTISEMENTVessels in Middle Eastern waters that are now trying to hide their location or are otherwise falsifying information are employing methods that have been perfected by Russian “shadow fleet” vessels evading sanctions related to the invasion of Ukraine in 2022, some experts say.“Shadow fleet tankers have been experimenting with stateless ID numbers,” said John C.K. Daly, a nonresident fellow at the Central Asia-Caucasus Institute in Washington who has been tracking Russian shadow ships. “What the Russians have been doing is altering the numbers.”When a ship is engaged in “spoofing,” as the practice is known, its captain can type in a false origin or destination or can pretend to be piloting another ship altogether. Vessels can also temporarily turn off their transponders, seeming to disappear in one place and reappear in another, sometimes with altered data.This approach has enabled Russia to keep up its energy exports and finance its war, generating up to $100 billion a year.It appears that vessels linked to Iran are using similar methods now, experts say. Some ships have gone dark, while sanctioned and falsely flagged vessels seem to still be active, a Windward report on Tuesday noted.Editors’ Picks “Under previous enforcement frameworks, including the December blockade of Venezuela, sanctioned and stateless tankers were primary targets for interdiction,” the report said. “The continued movement of similar vessel profiles indicates that operators are testing the practical limits of enforcement in real time.”By manipulating the global system meant to illuminate ship movements, so-called ghost or shadow vessels may compound confusion about the state of the Strait of Hormuz, even if in the end they cannot breach the American blockade.“Right now, the strait is a contested information environment,” said Erik Bethel, a partner at Mare Liberum, a maritime technology venture capital fund.Detection-avoidance tricksmay make it harder for the Navy to identify boats for interdiction. “A blockade is only as strong as the intelligence behind the interdictions,” Mr. Bethel said.The maritime system is complex. A vessel may be owned by one country, leased to another and travel under a third country’s flag of convenience, Mr. Bethel said. That makes determining who is truly behind any given journey a “really hard thing to do.”AdvertisementSKIP ADVERTISEMENTMaritime intelligence companies and militaries use an array of sources to stitch together information about vessels, including optical satellites, radar satellites and radio frequencies. They also collect information being transmitted by sailors, sometimes unwittingly, through their own personal technology, like Fitbits and cellphones.Still, whatever ruses they employ, vessels off Iran might only get so far. It is difficult to get out to the open ocean via a waterway as narrow as the Strait of Hormuz without being detected.A U.S. official said that more than 12 American military vessels were stationed in international waters in the Gulf of Oman. And on Tuesday, United States Central Command said that six merchant vessels had complied with directions by radio from U.S. forces to turn around and re-enter Iranian ports.“My expectation is that the U.S. Navy can sit out in the Gulf of Oman,” Mr. Daniel of Windward said. “I don’t think there’s a way to breach the blockade.” Ephrat Livni is a Times reporter covering breaking news around the world. She is based in Washington. Global Economic Warning: War in the Middle East has upended the world economy, the International Monetary Fund said, warning in a report that disruptions to oil markets could slow growth, fuel inflation and raise the possibility of a global recession. Strait of Hormuz: Shipowners and shipping experts said they did not expect a large number of vessels to return quickly to the strait because of concerns that the United States’ blockade plan lacked detail on how commercial vessels would be protected if they decided to go through the waterway. Iran’s Internet Blackout: As the country’s near-total internet blackout extends into its seventh week, Iranian businesses and academics are arguing that the shutdown not only violates citizens’ rights but further destabilizes the country’s already weakened economy. Israelis on the War: The ongoing war has left many in Israel despairing over how little they believe the fighting accomplished compared with the objectives laid out by their leaders.

@paulbristow79 $nwbo @alphavestcap x.com/paulbristow79/… 16h ADVENT BIOSERVICES - SAWSTONGreat visit in #Sawston to Advent Bioservices & Northwest Biotherapeutics who are working on cancer immunotherapies for brain tumors. This is personal. My dad died of a brain tumour & I shall do whatever I can to help them scale up & grow. 💙 💙

x.com/parkerici/stat… $nwbo x.com/peter_brit/sta… @alphavestcap x.com/peter_brit/sta… cancertreatmentreviews.com/article/S0305-… x.com/i/status/20439… nwbio.com nwbio.com/dendritic-cell…

Baxers $nwbo @alphavestcap Re: Baxers post# 818498 Saturday, March 21, 2026 4:00:11 PM One more little thing to bolster the case for an announcement by/ before end April/ early May. Something I just noticed that had alluded me before: In my original post I discussed mRESVIA, Moderna's mRNA therapy for Lower respiratory tract disease (LRTD), which I believe is the most similar treatment to DCVax amongst all other assessments that have followed the National Procedures pathway and which received a full MA 71 days after it's last CHM meeting. mRESVIA however had 3 CHM meetings, 200 days apart, 83 days apart and then 71 days until approval. What I hadn't noticed during my original review is the time it took mRESVIA to go from CHM 2 to the Approval announcement (83 + 71) is also 154 Days. The exact same length of time that it took Aucatzyl to go from it's 2nd CHM to the Announcement! I do not believe that this is a coincidence. In both cases I reckon this likely represents the maximum aggregate length of time after the 2nd CHM (Clock-On Day ~150) that the MHRA (+60 clock-on days) and Sponsor (+90 clock-off days) are allowed to respectively use (plus a stop/start buffer time allowance of ~4 days) in order to remain within the statutory clock-on limits of the HMR 2012 Schedule 11 framework - regardless of whether or not there needs to be a 3rd CHM meeting! We know from published minutes that DCVax didn't get discussed at the January 29/30th CHM. But it could have been discussed again at the February 26/27th CHM (which would be similar to mRESVIA's 83 day gap vs a potential 91 day gap for DCVax if it was discussed - the difference in which comes entirely down to the pre-planned CHM meeting dates). Based on the MHRA publishing schedule we wont know if DCVax was discussed a 3rd time until mid to late April as it takes 6-8 weeks. Nevertheless, whether DCVax is following a 2 or 3 CHM meeting schedule, I believe that the end result (if the maximum 210 Day statutory clock-on limit is used) will still be around the same time, end April/ beginning of May. See new posts Conversation alphavestcapital.com@alphavestcapBaxers Tuesday, April 14, 2026 5:30:27 PM Yep, today is the 137th day since CHM #2 No sign of the minutes from the February 26/27th CHM meeting yet, but I expect them published before the end of the month which will tell us if a 3rd CHM was required. Whether a 3rd CHM was needed or not, my expectation is still ~154 days from CHM #2. That happens to land us on a Friday May 1st. I sincerely doubt MHRA or the company will release news on a Friday and likely not a Monday either so my take for an MA announcement is either 4th/ 5th May. That is also 4-5 days past the forthcoming MHRA regulatory update day (with possible publication of the guidance on use of RWD in ECT) so the timing makes sense. 🤞$nwbo@alphavestcap